Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

NCT00350636 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.

NCT NCT00350636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00350636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension
Lead sponsor
Watson Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
May 31, 2007
Enrollment
789 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder